- Abstract
- 1. 서론
- 2. 연구 결과 및 토의
- 2.1. 국내의 광학이성질체 의약품 허가신청을 위한안전성 유효성 평가 제출서류의 범위
- 2.2. KFDA와 FDA에 제출된 안전성, 유효성 평가자료의 비교 연구
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A60024089
2011
Korean
405
KCI등재후보
학술저널
315-322(8쪽)
0
0
상세조회0
다운로드목차 (Table of Contents)
참고문헌 (Reference)
1 "식품의약품안전청 공고 제 2008 - 82호 : 의약품등 의 품목허가신고심사규정"
2 "미국 식품의약청 안전청"
3 최선옥, "광학활성의약품 개발과정에서의 입체화학적 문제" 한국약제학회 35 (35): 57-63, 2005
4 Investigation of chiral active substances (CPMP/III/ 3501/91), "http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/ 2009/09/WC500002816.pdf"
5 FDA Drug guidances: Development of new stereoisomeric drugs, "http:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm122883.htm"
6 Guidance for Industry : Stereochemical Issues in Chiral Drug Development, "Therapeutic Products Programme"
7 J. R. Brown, "Regulatory implications and chiral separations, In: A practical approach to chiral separations by liquid chromatography" Weinheim, VCH 57-62, 1994
8 의약품안전국, "K의약품등의 안전성유효성 심사 관 련해설서"
9 "International Federation of Pharmaceutical Manufactures Associations" IFPMA internet site
10 Q6A International Conference on Harmonisation, "Guidance on Q6A International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceutical Human Use" Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products
1 "식품의약품안전청 공고 제 2008 - 82호 : 의약품등 의 품목허가신고심사규정"
2 "미국 식품의약청 안전청"
3 최선옥, "광학활성의약품 개발과정에서의 입체화학적 문제" 한국약제학회 35 (35): 57-63, 2005
4 Investigation of chiral active substances (CPMP/III/ 3501/91), "http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/ 2009/09/WC500002816.pdf"
5 FDA Drug guidances: Development of new stereoisomeric drugs, "http:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm122883.htm"
6 Guidance for Industry : Stereochemical Issues in Chiral Drug Development, "Therapeutic Products Programme"
7 J. R. Brown, "Regulatory implications and chiral separations, In: A practical approach to chiral separations by liquid chromatography" Weinheim, VCH 57-62, 1994
8 의약품안전국, "K의약품등의 안전성유효성 심사 관 련해설서"
9 "International Federation of Pharmaceutical Manufactures Associations" IFPMA internet site
10 Q6A International Conference on Harmonisation, "Guidance on Q6A International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceutical Human Use" Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products
11 N. R. Srinivas, "Enantiomeric drug development: issues, considerations, and regulatory requirements" 90 : 1205-1215, 2001
12 J. M. Daniels, "Development of stereoisomeric (chiral) drugs: a brief review of scientific and regulatory considerations" 31 : 639-646, 1997
13 FDA Drug guidances, "Development of new stereoisomeric drugs"
14 FDA's policy statement for the development of new stereoisomeric drugs, "Chirality, Vol. 4" 338-340, 1992
15 I. K. Reddy, "Chirality in drug design and development" Marcel Dekker, New York 419-432, 2004
16 L. A. Nguyen, "Chiral drugs, an overview" 2 : 85-100, 2006
17 C. A. Challener, "Chiral drugs" Aldershot, Ashgate Publishing 15-25, 2002
18 G. Subramanian, "A practical approach to chiral separations by liquid chromatography" Weinheim, VCH 63-70, 1994
A Docking Study of Newly Found Natural Neuraminidase Inhibitor: Erystagallin A
Restrictions on the Entries of the Maps in Free Resolutions and SCr-condition
Sobolev Estimates for Certain Singular Curves
Stress and Nutrient Intakes by the Degree of Obesity in Female College Students
학술지 이력
연월일 | 이력구분 | 이력상세 | 등재구분 |
---|---|---|---|
2022 | 평가예정 | 신규평가 신청대상 (신규평가) | |
2021-12-01 | 평가 | 등재후보 탈락 (계속평가) | |
2020-12-01 | 평가 | 등재후보로 하락 (재인증) | |
2017-01-01 | 평가 | 등재학술지 유지 (계속평가) | |
2013-01-01 | 평가 | 등재학술지 선정 (등재후보2차) | |
2012-01-01 | 평가 | 등재후보 1차 PASS (등재후보1차) | |
2010-01-01 | 평가 | 등재후보학술지 선정 (신규평가) |
학술지 인용정보
기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
---|---|---|---|
2016 | 0.45 | 0.45 | 0.35 |
KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
0.28 | 0.25 | 0.24 | 0.05 |